Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (symbol: TNDM) is a leading medical device company committed to enhancing the lives of individuals with diabetes through continuous innovation and a customer-first approach. Based in San Diego, California, Tandem focuses on the design, development, and commercialization of advanced insulin pump technologies.
The company's flagship products include the t:slim X2™ insulin pump, noted for its unique ability to receive remote feature updates via a personal computer, and the t:flex® insulin pump, which is tailored for patients with higher insulin requirements. These devices are designed to offer users greater flexibility, control, and ease of use, significantly improving diabetes management.
In addition to these main products, Tandem has introduced the Mobi pump, a smaller, more discreet device, and is actively working on developing a tubeless pump to further enhance user convenience and experience. The company's product portfolio generates substantial revenue from both the insulin pumps themselves and the accompanying disposable infusion sets, which need regular replacement every 2 to 3 days.
Approximately 75% of Tandem's total revenue comes from the U.S. market, with the remaining sales derived from other developed countries. The company's strong focus on innovation and user experience has cemented its position as a trusted name in diabetes care.
For the latest updates and relevant information about Tandem Diabetes Care, Inc., including recent achievements, ongoing projects, financial performance, and strategic partnerships, stay tuned to our news section.
Note: This description is for informational purposes only and is not intended for product support or medical advice. In case of a medical emergency, please dial 911. For immediate assistance with Tandem products, contact the 24-hour customer support team at 877-801-6901, pressing 1 twice.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present a company update at the Piper Sandler Virtual Diabetes Symposium on Wednesday, May 25, 2022, at 11:00 AM ET. The presentation will be webcast live and archived for 30 days on their Investor Center website.
Tandem, based in San Diego, California, specializes in insulin delivery and diabetes technology, offering innovative products like the t:slim X2 insulin pump with Control-IQ technology.
Tandem Diabetes Care, Inc. (TNDM) reported Q1 2022 financial results, with sales rising by 25% to $175.9 million. Worldwide pump shipments increased by 11% to 28,095 units. Cash and equivalents reached $635.4 million, up $11.6 million this quarter. The company updated its 2022 guidance, estimating sales between $850 million and $865 million, reflecting a growth of 21% to 23%. Gross margins are projected at 54%. However, the operating loss increased to $15.3 million, and net loss reached $14.7 million, indicating challenges amidst growth.
Tandem Diabetes Care (NASDAQ:TNDM) announced positive real-world data for its t:slim X2 insulin pump with Control-IQ technology at the 15th International Conference on Advanced Technologies and Treatments for Diabetes in Barcelona. Results from the Control-IQ Observational study showed improvements in glycemic control and quality of life for 1,913 participants. Additionally, 95% of users transitioning from multiple daily injections successfully initiated Control-IQ technology within 14 days. The data emphasizes the technology's effectiveness across various age groups and prior delivery methods.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its first quarter 2022 financial results on May 4, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET (1:30 PM PT) to discuss the outcomes. Investors can dial in using (855) 427-4396 for toll-free and (484) 756-4261 for international access, with the conference ID being 2354706. An archived version of the webcast will be available for 30 days post-event on their Investor Center website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced a company update presentation scheduled for March 15, 2022, at 10:00 AM Eastern Time during the Oppenheimer 32nd Annual Healthcare Conference. The event will be webcast live, with an archive available for 30 days afterward. Interested parties can access the webcast link via Tandem's Investor Center website. Tandem specializes in innovative insulin delivery systems, including the t:slim X2 insulin pump, designed to enhance the lives of individuals with diabetes.
Tandem Diabetes Care reported robust financial performance for 2021, achieving a 41% increase in sales to $702.8 million. Worldwide pump shipments rose by 41% to 128,312 pumps, with a gross margin of 54%. The company posted a net income of $15.6 million, a turnaround from a $34.4 million loss in 2020. For 2022, Tandem projects sales between $845 million and $860 million, indicating 20% to 22% annual growth. The guidance supports continued investment in innovation and operational improvements.
Tandem Diabetes Care announces FDA clearance for the t:connect mobile app, the first smartphone application allowing bolus insulin delivery via both iOS and Android. This update provides users of the t:slim X2 insulin pump the convenience of programming and canceling bolus requests using their smartphones. Available for free as a software update to existing users, the feature will roll out in limited phases starting in spring. The app enhances diabetes management by displaying glucose trends and pump data securely.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will provide an update at two virtual investor conferences. The first is Citi’s 2022 Virtual Healthcare Conference on February 24, 2022, at 11:00am ET, followed by Cowen's 42nd Annual Health Care Conference on March 9, 2022, at 2:50pm ET. Both presentations will be webcast live, with archives available for 30 days on Tandem's Investor Center website. Tandem is focused on enhancing diabetes care through innovative products like the t:slim X2 insulin pump, which features remote software updates and integrated continuous glucose monitoring.
Tandem Diabetes Care (NASDAQ: TNDM) will announce its fourth quarter and full year 2021 results on February 22, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss the financial and operational highlights. Interested parties can join the call at (855) 427-4396 (toll-free) or (484) 756-4261 (international). An archived version of the webcast will be available for 30 days on their Investor Center website.
Tandem Diabetes Care announced key management appointments to enhance its leadership team for future growth. Rick Carpenter joins as Chief Technical Officer, bringing over 30 years of engineering experience. Libba Sapitsky becomes Senior Vice President of Customer Care, with extensive background in customer service operations. Rizwan Pervez is appointed Senior Vice President for Quality and Regulatory, having over 20 years in compliance leadership. These roles aim to support product expansion and pipeline execution as Tandem continues its mission to improve diabetes care.
FAQ
What is the current stock price of Tandem Diabetes (TNDM)?
What is the market cap of Tandem Diabetes (TNDM)?
What is Tandem Diabetes Care, Inc. known for?
Where is Tandem Diabetes Care, Inc. located?
What are the main products of Tandem Diabetes Care, Inc.?
How do the t:slim X2™ insulin pump updates work?
What percentage of Tandem Diabetes Care's revenue comes from the U.S.?
Does Tandem Diabetes Care offer customer support?
What recent products has Tandem Diabetes Care introduced?
What materials are required to replace in Tandem's insulin pumps?
What is the unique feature of the t:flex® insulin pump?
How does Tandem Diabetes Care innovate in diabetes care?
